Simeon George
Director/Board Member presso DESIGN THERAPEUTICS, INC.
Patrimonio netto: 71 M $ in data 31/03/2024
Profilo
Simeon J.
George founded SR One Capital Management LP in 2020, where he is working as CEO from 2020 and Nkarta, Inc. in 2015, where he worked as Independent Director from 2015 to 2017.
Dr. George also currently works at GSK Equity Investments Ltd., as Chief Executive Officer from 2007, Bird Rock Bio Sub, Inc., as Director from 2009, Auxogyn, Inc., as Director, eFFECTOR Therapeutics Operations, Inc., as Director from 2013, CRISPR Therapeutics AG, as Independent Non-Executive Director from 2015, Battersea Biotech, LLC, as Director, Simcha Therapeutics Holding Co. LLC, as Director, Design Therapeutics, Inc., as Lead Independent Director from 2023, Simcha Therapeutics, Inc., as Director, Rezo Therapeutics, Inc., as Director, and Nkarta, Inc., as Independent Director from 2020.
Dr. George also formerly worked at HTG Molecular Diagnostics, Inc., as Independent Director from 2011 to 2015, Genocea Biosciences, Inc., as Independent Director from 2013 to 2014, Semprus BioSciences Corp., as Director from 2010 to 2012, Principia Biopharma, Inc., as Independent Director from 2011 to 2020, Turning Point Therapeutics, Inc., as Independent Non-Executive Director from 2017 to 2022, Progyny, Inc., as Director from 2012 to 2019, Merrill Lynch & Co., Inc., as Principal, and Goldman Sachs & Co. LLC, as Associate.
Dr. George received his undergraduate degree from The Johns Hopkins University, Masters Business Admin degree from The Wharton School of the University of Pennsylvania, and doctorate degree from the University of Pennsylvania Medical Center.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CRISPR THERAPEUTICS AG
1.25% | 27/02/2024 | 1 048 951 ( 1.25% ) | 71 M $ | 31/03/2024 |
NKARTA, INC.
-.--% | 25/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
| 31/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Simeon George
| Società | Posizione | Inizio |
|---|---|---|
| CRISPR THERAPEUTICS AG | Director/Board Member | 29/04/2015 |
| DESIGN THERAPEUTICS, INC. | Director/Board Member | 01/02/2020 |
| NKARTA, INC. | Director/Board Member | 01/02/2020 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Chief Executive Officer | 01/01/2007 |
Rezo Therapeutics, Inc.
 Rezo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rezo Therapeutics, Inc. is a drug discovery company based in San Francisco, CA. The company's mission is to revolutionize traditional drug development by integrating proteomics, genetics, structural biology, chemistry, artificial intelligence, and machine learning to create maps of molecular disease networks. Rezo's initial focus is on oncology, but they plan to explore additional therapeutic areas through collaborations and partnerships. The company was founded by Natalia Jura, Kevan Shokat, Nevan Krogan, Sourav Bandyopadhyay, Norbert W. Bischofberger, and George A. Scangos, with Nevan Krogan serving as CEO since incorporation. | Director/Board Member | - |
Simcha Therapeutics Holding Co. LLC
 Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Simcha Therapeutics Holding Co. LLC is a biopharmaceutical company which engages in developing an engineered interleukin therapy. The company was founded in 2018 and is headquartered in New Haven, CT. | Director/Board Member | - |
Simcha Therapeutics, Inc.
 Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Simcha Therapeutics, Inc. operates as a biopharmaceutical company that develops engineered interleukin therapy products. The company was founded by Aaron Ring in 2018 and is headquartered in New Haven, CT. | Director/Board Member | - |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Chief Executive Officer | 01/09/2020 |
Battersea Biotech, LLC
 Battersea Biotech, LLC Pharmaceuticals: MajorHealth Technology Battersea Biotech, LLC manufactures pharmaceutical products for cancer treatment. The company is headquartered in San Francisco, CA. | Director/Board Member | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di Simeon George
| Società | Posizione | Fine |
|---|---|---|
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Simeon George
| The Johns Hopkins University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania Medical Center | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| PROGYNY, INC. | Commercial Services |
| NKARTA, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
 Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch & Co., Inc. provided wealth management, securities trading and sales, corporate finance and investment banking services. Merrill Lynch was a global trader and underwriter of securities and derivatives across a range of asset classes and serve as a strategic advisor to governments, institutions and individuals worldwide. The company was founded in 1913 and was headquartered in Charlotte, NC. | Finance |
Semprus BioSciences Corp.
 Semprus BioSciences Corp. Pharmaceuticals: GenericHealth Technology Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Health Technology |
Auxogyn, Inc.
 Auxogyn, Inc. BiotechnologyHealth Technology Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Battersea Biotech, LLC
Battersea Biotech, LLC Pharmaceuticals: MajorHealth Technology Battersea Biotech, LLC manufactures pharmaceutical products for cancer treatment. The company is headquartered in San Francisco, CA. | Health Technology |
Simcha Therapeutics Holding Co. LLC
Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Simcha Therapeutics Holding Co. LLC is a biopharmaceutical company which engages in developing an engineered interleukin therapy. The company was founded in 2018 and is headquartered in New Haven, CT. | Health Technology |
| Design Therapeutics, Inc. | |
Simcha Therapeutics, Inc.
Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Simcha Therapeutics, Inc. operates as a biopharmaceutical company that develops engineered interleukin therapy products. The company was founded by Aaron Ring in 2018 and is headquartered in New Haven, CT. | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Finance |
Rezo Therapeutics, Inc.
Rezo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rezo Therapeutics, Inc. is a drug discovery company based in San Francisco, CA. The company's mission is to revolutionize traditional drug development by integrating proteomics, genetics, structural biology, chemistry, artificial intelligence, and machine learning to create maps of molecular disease networks. Rezo's initial focus is on oncology, but they plan to explore additional therapeutic areas through collaborations and partnerships. The company was founded by Natalia Jura, Kevan Shokat, Nevan Krogan, Sourav Bandyopadhyay, Norbert W. Bischofberger, and George A. Scangos, with Nevan Krogan serving as CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Simeon George
